We provide funding so the brightest minds in pediatric cancer research can find the next big breakthrough.
What We Fund
To call pediatric cancer research “underfunded” is putting it lightly. Among the 12 different types of childhood cancers – yes, there are 12, with dozens of subtypes – the rarest of cancers go for decades without any progress.
Although we’ve made great strides in treating some childhood cancers in the past 50 years, current treatment protocols cause long-term, chronic health problems for survivors like organ damage, fertility issues, and even secondary cancers.
We seek solutions for the underdogs – the rare childhood cancers – so kids living with cancer don’t just survive, but thrive.
Since 2010, we have awarded $900,000 in Childhood Cancer Research Grants to thirteen institutions worldwide. Our researchers are searching for more effective treatment options, and for a better understanding of how childhood cancers behave.
Glypican-3 specific T-cells for the Adoptive Immunotherapy of Pediatric Liver Cancers
Andras Heczey M.D.
Texas Children’s Hospital/Baylor College of Medicine
Identification and targeting of circulating Ewing’s sarcoma stem cells
Masanori Hayashi, M.D.
Johns Hopkins University
Identification of novel cdk4/6 effectors in T-cell acute lymphoblastic leukemia
John Carter, M.D., Ph.D.
Fred Hutchinson Cancer Research Center at Seattle Children’s Hospital
Detection of novel autoantibodies in children with OMS
Bethan Lang, M.D.
Targets of the Intrathecal B-Cell Response in Pediatric Opsoclonus Myoclonus Syndrome
Gregory Owens, Ph.D.
University of Colorado School of Medicine
miRNAs secreted by tumor associated macrophages and resistance in Neuroblastoma
Muller Fabbri M.D., Ph.D.
Saban Research Institute at Children’s Hospital Los Angeles and the University of Southern California *RENEWED!*
The role of the de-ubiquitinase USP44 in childhood germ cell tumorigenesis
Ying Zhang, Ph.D.
Development of anti-tumor molecules targeting the Wilms tumor oncogene, LIN28B
Shilpa Pathak, Ph.D.
Roswell Park Cancer Institute
Role of the GAB2-SHP2 network in childhood neuroblastoma pathogenesis
Shizen Zhu, M.D., Ph.D.
Dana-Farber Cancer Institute
Phase I/II clinical trial evaluating NK cell immunotherapy in relapsed and refractory pediatric solid tumors
Monica Thakar, M.D.
Children’s Hospital of Wisconsin/Medical College of Wisconsin
Elucidating Epigenetic Mechanisms for Therapeutic Targeting in Aggressive Pediatric Cancers
Boris Wilson, Ph.D.
Dana-Farber Cancer Institute
Develop Small Molecule Yap Inhibitors to Treat Childhood Cancer
Chungling Yi, Ph.D.
Lombardi Cancer Center at Georgetown University
Phase I Dose Escalation Study of Sorafenib/Irinotecan Combination Therapy in Pediatric Relapsed Solid Tumors
Holly Meany, M.D.
Children’s National Medical Center *RENEWED!*
Alternative Lengthening of Telomeres in Neuroblastoma
Loretta Lau, M.D.
The Children’s Hospital at Westmead, Sydney, Australia
Identification of Clinical Biomarkers of Wilms Tumor Using High Accuracy Mass Spectroscopy Urine Proteome Profiling
Elizabeth Mullen, M.D.
Dana-Farber Cancer Institute *RENEWED!*
Basic Research helps us build knowledge and understanding of the fundamental aspects of cancer. Sometimes basic research is called “pure” research, as it is not focused on a particular problem or application, but lays the foundation for advancements that can lead to applied gains in the future.
Translational Research takes the findings from basic scientific research and attempts to make those findings useful in practical applications. To put it simply, this type of research “translates” science into meaningful health outcomes. It brings science from “bench to bedside.”
Clinical Research determines the safety and effectiveness of medications, devices, diagnostic products or treatment regimens intended for humans. An example is a clinical trial in which children are enrolled to test the efficacy of a newly developed drug.